Jinnong Zhang

Jinnong Zhang

Auto-generated profile, based on publicly available information

Jinnong Zhang

Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
JZJinnong Zhang
Jinnong Zhang
LZLuqian Zhou
Luqian Zhou
YYYuqiong Yang
Yuqiong Yang
WPWei Peng
Wei Peng
WWWenjing Wang
Wenjing Wang
XCXuelin Chen
Xuelin Chen

15 September 1999 in Respiration
Verified
Journal Article
Closed access
PDF file
KBKonrad E. Bloch
Konrad E. Bloch
OSOtto Schoch
Otto Schoch
JZJinnong N. Zhang
Jinnong N. Zhang
ERErich W. Russi
Erich W. Russi
Background: The Epworth Sleepiness Scale (ESS) is a questionnaire widely used in English speaking countries for assessment of subjective daytime sleepiness. Objective: Our purpose was to translate and validate the ESS for use in German-speaking countries. Methods: A German translation of the ESS was administered to 159 healthy German-speaking Swiss and to 174 patients with various sleep disorders. Results: The mean ± SD of ESS scores in normals was 5.7 ± 3.0, in patients it was 13.0 ± 5.1 (p < 0.001). Scores were not correlated with age or gender but with the percentage of time spent at an oxygen saturation <90% (R = 0.35, p < 0.001), and the respiratory disturbance index (R = 0.26, p < 0.001) in primary snorers and sleep apnea patients. Item analysis confirmed internal consistency of the scale (Cronbach α = 0.60 in normals, and 0.83 in patients). Follow-up scores in 25 sleep apnea patients on treatment showed a reduction by 7 ± 5 points (p < 0.05). Conclusions: Our data validate the ESS for application in German-speaking populations. The simplicity, reliability and the apparent lack of relevant influences of language and cultural background on performance of the ESS makes it a valuable tool for clinical management and research.

1 July 2000 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KBKonrad E. Bloch
Konrad E. Bloch
AIAngelo Iseli
Angelo Iseli
JZJinnong N. Zhang
Jinnong N. Zhang
XXXiaobin Xie
Xiaobin Xie
VKVladimir Kaplan
Vladimir Kaplan
ERErich W. Russi
Erich W. Russi
Our purpose was to compare the effectiveness and side effects of a novel, single-piece mandibular advancement device (OSA-Monobloc) for sleep apnea therapy with those of a two-piece appliance with lateral Herbst attachments (OSA-Herbst) as used in previous studies. An OSA-Monobloc and an OSA-Herbst with equal protrusion were fitted in 24 obstructive sleep apnea patients unable to use continuous positive airway pressure (CPAP) therapy. After an adaptation period of 156 ± 14 d (mean ± SE), patients used the OSA-Monobloc, the OSA-Herbst, and no appliance in random order, using each appliance for 1 wk. Symptom scores were recorded and sleep studies were done at the end of each week. Several symptom scores were significantly improved with both appliances, but to a greater degree with the OSA-Monobloc. Epworth Sleepiness Scale scores were 8.8 ± 0.7 with the OSA-Herbst, and 8.6 ± 0.8 with the OSA-Monobloc devices, and 13.1 ± 0.9 without therapy (p < 0.05 versus both appliances). The apnea/hypopnea index was 8.7 ± 1.5/h with the OSA-Herbst and 7.9 ± 1.6/h with the OSA-Monobloc device, and 22.6 ± 3.1/h without therapy (p < 0.05 versus both appliances). Side effects were mild and of equal prevalence with both appliances. Fifteen patients preferred the OSA-Monobloc, eight patients had no preference, and one patient preferred the OSA-Herbst device (p < 0.008 versus OSA-Monobloc). We conclude that both the OSA-Herbst and the OSA-Monobloc are effective therapeutic devices for sleep apnea. The OSA-Monobloc relieved symptoms to a greater extent than the OSA-Herbst, and was preferred by the majority of patients on the basis of its simple application.

1 August 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
LMLing Ma
Ling Ma
WWWenjing Wang
Wenjing Wang
JGJehane Michael Le Grange
Jehane Michael Le Grange
XWXiaorong Wang
Xiaorong Wang
SDShuaixian Du
Shuaixian Du
JZJin-Nong Zhang
Jin-Nong Zhang
Purpose: To differentiate between respiratory infections caused by SARS-CoV-2 and other respiratory pathogens during the COVID-19 outbreak in Wuhan, we simultaneously tested for SARS-CoV-2 and pathogens associated with CAP to determine the incidence and impact of respiratory coinfections in COVID-19 patients. Patients and Methods: We included 250 patients who were diagnosed with COVID-19. RT-PCR was used to detect influenza A, influenza B and respiratory syncytial viruses. Chemiluminescence immunoassays were used to detect IgM antibodies for adenovirus, Chlamydia pneumoniae and Mycoplasma pneumoniae in the serum of patients. Based on these results, we divided the patients into two groups, the simple SARS-CoV-2-infected group and the coinfected SARS-COV-2 group. Coinfected patients were then further categorized as having a coinfection of viral pathogen (CoIV) or coinfection of atypical bacterial pathogen (CoIaB). Results: No statistically significant differences were found in age, gender, the time taken to return negative SARS-CoV-2 nucleic acid test results, length of hospital stays, and mortality between the simple SARS-CoV-2 infection group and the coinfection group. Of the 250 hospitalized COVID-19 patients, 39 (15.6%) tested positive for at least one respiratory pathogen in addition to SARS-CoV-2. A third of these pathogens were detected as early as the 1st week after symptom onset and another third were identified after more than three weeks. The most detected CAP pathogen was C. pneumoniae (5.2%), followed by the respiratory syncytial virus (4.8%), M. pneumoniae (4.4%) and adenovirus (2.8%). Patients coinfected with viral pathogens (CoIV) (n=18) had longer hospital stays when compared to patients coinfected with atypical bacterial pathogens (CoIaB) (n=21). Except for one fatality, the remaining 38 coinfected patients all recovered with favourable outcomes. Conclusion: Coinfections in COVID-19 patients are common. The coinfecting pathogens can be detected at variable intervals during COVID-19 disease course and remain an important consideration in targeted treatment strategies for COVID-19 patients.

1 March 2000 in European Respiratory Journal
Verified
Journal Article
Closed access
VKV. Kaplan
V. Kaplan
JZJ.N. Zhang
J.N. Zhang
ERE.W Russi
E.W Russi
KBK.E Bloch
K.E Bloch
The potential of respiratory inductive plethysmography (RIP) to detect inspiratory flow limitation during sleep was investigated. Sixteen sleep apnoea patients underwent polysomnography. Airflow by a flowmeter attached to a nasal mask, oesophageal and mask pressure were recorded along with calibrated RIP. Presence of inspiratory flow limitation was defined by constant or decreasing flow without pressure dependence throughout significant portions of inspiration, its absence by a linear or mildly alinear pressure:airflow relationship. Based on this standard, three of various computerized RIP derived parameters, with highest performance to detect flow limitation, were identified. They were combined to an inspiratory flow limitation, (IFL)-Index(RIP), which was validated prospectively in another 10 sleep apnoea patients. RIP derived fractional inspiratory time, peak to mean inspiratory flow ratio, and ribcage contribution to tidal volume had the highest accuracy to detect flow limitation (area under the receiver operating characteristic (ROC) curves 0.81, 0.76, 0.76, respectively, 160 comparisons). Prospective validation revealed an area under the ROC curve for the IFL-Index(RIP) to detect flow limitation of 0.89 (95% confidence interval 0.85 to 0.93, 200 comparisons) with sensitivity and specificity at the point of equality of 80%. It is concluded that inspiratory flow limitation may be assessed by computer assisted analysis of respiratory inductive plethysmography derived breathing patterns with clinically acceptable accuracy.

1 August 1997 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KBKonrad E. Bloch
Konrad E. Bloch
YLYiming Li
Yiming Li
JZJinnong Zhang
Jinnong Zhang
RBRoland Bingisser
Roland Bingisser
VKVladimir Kaplan
Vladimir Kaplan
ERErich W. Russi
Erich W. Russi
Surgical lung volume reduction may improve pulmonary function and dyspnea in advanced pulmonary emphysema. To investigate mechanisms of these beneficial effects we studied breathing patterns before and after surgery. Nineteen patients with diffuse pulmonary emphysema (FEV1 < 35% of predicted, total lung capacity > 130% predicted) were studied within 1 mo before, and 1.5 to 7 mo after thoracoscopic volume reduction. Changes of rib cage and abdominal volumes were monitored with calibrated respiratory inductive plethysmography for 20 to 60 min during natural breathing at rest. Pulmonary function and dyspnea were also assessed. Postoperative tidal volumes, respiratory cycle times, and minute ventilation were not significantly different from preoperative values. The contribution of abdominal volume changes to tidal volumes increased from a mean ± SD of 43 ± 17% preoperatively to 58 ± 14% postoperatively (p = 0.03). The fraction of inspiratory time with abdominal paradoxical motion decreased from 12.3 ± 8.3% preoperatively to 5.1 ± 5.1% postoperatively (p = 0.02). The phase shift between rib cage and abdominal motion was reduced postoperatively. Hyperinflation, airway obstruction, and subjective ratings of dyspnea were significantly improved. The better synchronization of rib cage–abdominal motion and the greater contribution of abdominal volume changes to tidal volumes are consistent with a reduction of inspiratory loading and a greater force-generating capacity of the diaphragm after surgery.